



MEDICARE FORM

Herceptin® (trastuzumab), Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), Herzuma (trastuzumab-pkrb), Kadcyła® (ado-trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Perjeta® (pertuzumab) and Trazimera (trastuzumab-qyyp)
Precertification Request

Page 1 of 3

(All fields must be completed and legible for Precertification Review.)

For Medicare Advantage Part B:

PHONE: 1-866-503-0857

FAX: 1-844-268-7263

For other lines of business:

Please use other form.

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy: Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name: _____ Last Name: _____
Address: _____ City: _____ State: _____ ZIP: _____
Home Phone: _____ Work Phone: _____ Cell Phone: _____
DOB: _____ Allergies: _____ E-mail: _____
Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____ Does patient have other coverage? Yes No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____ Insured: _____

C. PRESCRIBER INFORMATION

First Name: _____ Last Name: _____ (Check One): M.D. D.O. N.P. P.A.
Address: _____ City: _____ State: _____ ZIP: _____
Phone: _____ Fax: _____ St Lic #: _____ NPI #: _____ DEA #: _____ UPIN: _____
Office Contact Name: _____ Phone: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
 Self-administered Physician's Office
 Outpatient Infusion Center Phone: _____
Center Name: _____
 Home Infusion Center Phone: _____
Agency Name: _____
Address: _____
 Administration code(s) (CPT): _____

Dispensing Provider/Pharmacy:
 Physician's Office Retail Pharmacy
 Specialty Pharmacy Other _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for: Herceptin (trastuzumab) Perjeta (pertuzumab) Kadcyła (ado-trastuzumab emtansine) Ogivri (trastuzumab-dkst)
 Ontruzant (trastuzumab-dttb) Herzuma (trastuzumab-pkrb) Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)
 Kanjinti (trastuzumab-anns) Trazimera (trastuzumab-qyyp)

Dose: _____ Frequency: _____ HCPCS Code: _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required):
 Yes No Does the patient have HER2 protein overexpression documented by one of the following?
→ **Check all that apply:**
 Immunohistochemistry (IHC) Assay level of 3+
→ Results _____ Date of Test: ____ / ____ / ____
 Positive Fluorescent in situ hybridization (FISH) HER2 gene copy of greater than 6 signals/nucleus
→ Results _____ Date of Test: ____ / ____ / ____
 Positive Fluorescent in situ hybridization (FISH) HER2 gene/ chromosome 17 ratio greater than or equal to 2.0
→ Results _____ Date of Test: ____ / ____ / ____

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera. Preferred products may vary based on indication.

Yes No Has the patient had prior therapy with Herzuma, Ogivri, or Ontruzant within the last 365 days?
 Yes No Has the patient had a trial, intolerance, or contraindication to Herceptin, Herceptin Hylecta, Kanjinti, or Trazimera?

Continued on next page



MEDICARE FORM

**Herceptin® (trastuzumab), Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), Herzuma (trastuzumab-pkrb), Kadcyła® (ado-trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Perjeta® (pertuzumab) and Trazimera (trastuzumab-qyyp)
Precertification Request**

For Medicare Advantage Part B:
PHONE: 1-866-503-0857
FAX: 1-844-268-7263

For other lines of business:
Please use other form.

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Page 2 of 3

(All fields must be completed and legible for Precertification Review.)

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

Please explain if there are any other medical reason(s) that the patient cannot use Herceptin, Herceptin Hylecta, Kanjinti, or Trazimera.

HERCEPTIN (trastuzumab):

Esophageal adenocarcinoma Gastric adenocarcinoma Esophageal-gastric junction adenocarcinoma

Yes No Will Herceptin (trastuzumab) be used as palliative therapy?

Yes No Will Herceptin (trastuzumab) be used in combination with systemic chemotherapy?

→ Please provide the name of the systemic chemotherapy: _____

Endometrial carcinoma

Yes No Does the patient have advanced (stage III/IV) disease?

Yes No Does the patient have a documented diagnosis of uterine serous carcinoma?

Yes No Does the patient have recurrent disease?

Yes No Will Herceptin (trastuzumab) be used in combination with carboplatin and paclitaxel?

Salivary gland tumors

Yes No Does the patient have recurrent disease with distant metastases?

Please indicate how Herceptin (trastuzumab) will be used: single agent Other: Please explain: _____
 in combination with systemic chemotherapy: Name of systemic chemotherapy: _____

HER2 positive breast cancer

Yes No Does the patient have recurrent, metastatic, stage IV disease or leptomeningeal metastases from breast cancer (as intracerebrospinal fluid treatment)? recurrent disease metastatic disease stage IV disease

leptomeningeal metastases from breast cancer (as intracerebrospinal fluid treatment)

→ Yes No Will Herceptin (trastuzumab) be used as pre-operative (neoadjuvant) systemic therapy?

→ Please select in which of the following settings Herceptin (trastuzumab) will be used:

Node-positive disease likely to become node-negative with pre-operative systemic therapy

Locally advanced disease Individuals who fulfill criteria for breast-conserving surgery except for tumor size

None of the above

Yes No Will Herceptin (trastuzumab) be used as adjuvant therapy?

Yes No Will Herceptin (trastuzumab) be used as part of a complete treatment regimen?

HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk):

HER2 positive breast cancer

Please select which of the following applies to the patient's disease stage:

Early stage HER2-overexpressing breast cancer

→ Yes No Will Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) be used as adjuvant therapy?

Metastatic HER2-overexpressing breast cancer

Other

PERJETA (pertuzumab) with HERCEPTIN (trastuzumab):

(please ensure dosing and instructions for both drugs are documented in section E) **HER2 positive breast cancer**

Please select which type of treatment Perjeta (pertuzumab) and Herceptin (trastuzumab) is being used for:

Adjuvant therapy

→ Yes No Is the patient's disease node-positive or at high-risk for recurrence?

→ Please select: Node-positive At high-risk for recurrence Other: _____

Preoperative (neoadjuvant) therapy

→ Please select in which of the following settings Perjeta (pertuzumab) with Herceptin (trastuzumab) will be used:

Node-positive disease likely to become node-negative with pre-operative systemic therapy

Individuals who desire breast preservation and fulfill criteria for breast-conserving surgery except for tumor size

Locally advanced disease None of the above

Other

→ Please indicate which applies to the patient's disease: Recurrent disease Metastatic disease

Yes No Does the patient have symptomatic visceral disease or visceral crisis?

→ Please specify: Symptomatic visceral disease Visceral crisis

Continued on next page



MEDICARE FORM

Herceptin® (trastuzumab), Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk), Herzuma (trastuzumab-pkrb), Kadcyła® (ado-trastuzumab), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Perjeta® (pertuzumab) and Trazimera (trastuzumab-qyyp)
Precertification Request

For Medicare Advantage Part B:

PHONE: 1-866-503-0857

FAX: 1-844-268-7263

For other lines of business:

Please use other form.

Note: Herzuma, Ogivri, and Ontruzant are non-preferred. The preferred products are Herceptin, Herceptin Hylecta, Kanjinti, and Trazimera.

Page 3 of 3

(All fields must be completed and legible for Precertification Review.)

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.

KADCYLA (ado-trastuzumab emtansine):

Yes No Does the patient have a documented diagnosis of HER2-positive non-small cell lung cancer?

Yes No Is the patient being treated for HER2-positive recurrent or metastatic breast cancer?

Yes No Will Kadcyła (ado-trastuzumab emtansine) be used as adjuvant systemic therapy?

Yes No Has the patient received neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab?

Please provide the date range of use: ____ / ____ / ____ to ____ / ____ / ____

Yes No Does the patient have a residual disease after receiving neoadjuvant therapy?

Please indicate which applies: recurrent breast cancer metastatic breast cancer

Yes No Does the patient have symptomatic visceral disease or visceral crisis?

Please indicate the type of breast cancer: Hormone receptor- negative Hormone receptor-positive Unknown Other

Yes No Is the breast cancer refractory to endocrine therapy?

Please select which of the following endocrine therapy the patient is refractory to:

Nonsteroidal aromatase inhibitors (anastrozole and letrozole)

Steroidal aromatase inhibitors (exemestane)

Estrogen receptor (ER) antagonists (tamoxifen or toremifene)

ER down-regulators (fulvestrant) High-dose estrogen (ethinyl estradiol)

Androgens (fluoxymesterone) Other: Please explain: _____

Please specify: symptomatic visceral disease visceral crisis

Yes No Will Kadcyła (ado-trastuzumab emtansine) be used as a single agent?

Yes No Will Kadcyła (ado-trastuzumab emtansine) be used concomitantly with Herceptin (trastuzumab), Tykerb (lapatinib), or Perjeta (pertuzumab)?

For Continuation Requests (clinical documentation required):

Yes No Has the patient experienced disease progression or unacceptable toxicity while on HER2 therapy?

→ Please indicate: Disease progression Unacceptable toxicity

HERCEPTIN (trastuzumab):

For HER2-positive breast cancer only:

Yes No Is there clinical evidence of distant metastatic disease?

→ Please provide initial start date: ____ / ____ / ____

HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk):

Yes No Will Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) be used in adjuvant settings?

→ Please provide the initial start date: ____ / ____ / ____

PERJETA (pertuzumab) with HERCEPTIN (trastuzumab):

Yes No Is there clinical evidence of distant metastatic disease?

→ Please provide initial start date: ____ / ____ / ____

KADCYLA (ado-trastuzumab emtansine):

Yes No Is Kadcyła (ado-trastuzumab emtansine) being used concomitantly with Herceptin (trastuzumab), Tykerb (lapatinib), or Perjeta (pertuzumab)?

Yes No Is there clinical evidence of metastatic disease?

→ Please provide initial start date: ____ / ____ / ____

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.